Venture Life (VLG) AI Stock Analysis

• Market Cap: £84.57M
• Dividend Yield: N/A
• Average Volume (3M): 139.02K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.39
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: UK
• Employees: 165
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 126,217,160
• 10 Day Avg. Volume: 191,491
• 30 Day Avg. Volume: 139,016
• PEG Ratio: 1.18
• Price to Book (P/B): 0.66
• Price to Sales (P/S): 1.87
• P/FCF Ratio: 5.96
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 65 Neutral
• Price Target: 66.00p ▲(0.76% Upside)

Venture Life's stock score is primarily supported by strong technical indicators and positive corporate events, such as share buybacks and insider buying, which suggest confidence in future prospects. However, the high P/E ratio and profitability challenges weigh down the score, indicating potential overvaluation and financial risks.

Positive Factors

Cash Generation

Improved free cash flow indicates strong cash generation, providing financial flexibility for investments and debt management.

Balance Sheet Strength

A stable equity base and manageable debt levels enhance financial resilience, supporting long-term operational stability.

Operating Cash Flow

Robust operating cash flow suggests efficient cash operations, ensuring liquidity and supporting ongoing business activities.

Negative Factors

Declining Revenue

Declining revenues can impact market position and long-term growth prospects, necessitating strategic adjustments to reverse the trend.

Profitability Issues

Negative profitability margins highlight operational challenges, potentially affecting investment capacity and shareholder returns.

Margin Pressure

Decreasing margins indicate rising costs or pricing pressures, which could erode competitive advantage and financial performance.

Venture Life Business Overview & Revenue Model

Company Description

Venture Life Group plc develops and commercializes oral care products, food supplements, medical devices, dermo-cosmetics, and topical products for the ageing population in the United Kingdom, the Netherlands, China, Germany, Italy, Switzerland, rest of Europe, and internationally. It operates through Venture Life Brands and Customer Brands segments. The company offers neurology products, including NeuroAge, NeuroAge Sleep, and NeuroAge NRG food supplements to enhance alertness, cognitive function, and mental performance in healthy brain; and Original Bioscalin to treat and prevent hair loss, hair thinning, and baldness. It also provides Fungal Nail Solution, which helps to treat and prevent fungal infections; and Fungal Nail Cleanser for the hygiene of hands and feet prone to fungal nail infections under the Myco Clear brand name. In addition, the company offers UltraDEX product for bad breath; Dently Dual Action, a mouthwash, which lifts and removes plaque and bacteria from the teeth and gums; and Procto-eze plus for anal irritation, including haemorrhoids condition. Further, it provides women healthcare products comprising vonalei bacterial vaginosis, a refreshing gel; vonalei Vaginal Atrophy, a vaginal cream; vonalei candidiasis, a soothing cream-gel for thrush; and vonalei intimate cleansing foam. Additionally, it offers Cleansing Foam, Cleansing Cream, and Serum under the Rosa calma brand name; and skincare ranges to hydrate, nourish, and recondition the skin, as well as to prevent the lines and wrinkles under the Lubatti Classic and the Lubatti Anti-age brand names. The company sells its products through a network of international partners, retail pharmacies, as well as grocery multiple retailers. Venture Life Group plc was incorporated in 2005 and is headquartered in Bracknell, the United Kingdom.

How the Company Makes Money

Venture Life generates revenue primarily through the sale of its consumer healthcare products, which are distributed through various channels, including pharmacies, supermarkets, and online platforms. The company benefits from a diversified revenue model that includes both direct sales and partnerships with third-party distributors. Key revenue streams include product sales from its branded and private label offerings, as well as licensing agreements that allow other companies to market its products under their own brands. Additionally, Venture Life has established significant partnerships with retailers and healthcare providers, enhancing its market reach and contributing to its earnings through increased product visibility and accessibility.

Venture Life Financial Statement Overview

Summary

Venture Life faces challenges in maintaining revenue and profitability, as seen in the income statement. However, balance sheet strength and improving cash flows provide some financial resilience. The company needs to address declining revenues and margins to improve its financial health.

Income Statement

The company shows a declining revenue trend with a significant drop from 2023 to 2024. Gross Profit and Net Income margins are under pressure, turning negative in 2024, indicating profitability issues. The EBIT and EBITDA margins remain positive but have decreased, reflecting operational challenges.

Balance Sheet

The balance sheet reflects a stable equity base with a manageable debt-to-equity ratio. However, a slight increase in liabilities over time may pose a risk to financial stability. The equity ratio remains healthy, suggesting a strong asset base relative to liabilities.

Cash Flow

The cash flow statement shows improvement in free cash flow in recent years, indicating better cash generation despite declining net income. Operating cash flow remains robust relative to net income, suggesting efficient cash operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	18.53M	26.59M	51.41M	43.98M	32.76M	30.08M
Gross Profit	9.88M	12.19M	20.15M	17.66M	12.96M	12.85M
EBITDA	11.40M	4.32M	9.95M	7.61M	5.16M	5.60M
Net Income	-88.00K	-314.00K	921.00K	520.00K	2.40M	2.37M
Balance Sheet
Total Assets	124.91M	124.49M	119.50M	125.29M	103.63M	92.68M
Cash, Cash Equivalents and Short-Term Investments	2.01M	3.05M	5.62M	5.63M	5.24M	42.09M
Total Debt	23.28M	23.86M	24.39M	26.85M	12.73M	11.18M
Total Liabilities	49.68M	49.08M	43.24M	49.63M	30.47M	20.57M
Stockholders Equity	75.23M	75.41M	76.25M	75.66M	73.16M	72.11M
Cash Flow
Free Cash Flow	1.41M	8.34M	5.81M	1.36M	-2.66M	637.00K
Operating Cash Flow	1.44M	8.35M	8.22M	5.57M	601.00K	2.71M
Investing Cash Flow	-875.00K	-11.29M	-5.34M	-11.69M	-39.18M	-7.53M
Financing Cash Flow	-337.00K	1.78M	-2.81M	6.92M	1.50M	36.27M

Venture Life Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 65.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:VLG, the sentiment is Positive. The current price of 65.5 is above the 20-day moving average (MA) of 65.15, above the 50-day MA of 60.81, and above the 200-day MA of 54.94, indicating a bullish trend. The MACD of 1.72 indicates Positive momentum. The RSI at 68.58 is Neutral, neither overbought nor oversold. The STOCH value of 68.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:VLG.

Venture Life Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HLN	73 Outperform	£32.73B	21.86	9.35%	1.51%	-2.12%	42.10%
VLG	65 Neutral	£84.57M	―	―	―	―	―
STX	63 Neutral	£111.49M	-5.65	-396.71%	―	93.48%	51.18%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
AGY	57 Neutral	£730.83M	-14.17	―	―	-0.28%	22.94%
PXS	51 Neutral	£22.87M	-32.50	-51.21%	―	61.13%	33.33%
N4P	42 Neutral	£4.16M	-2.08	-73.08%	―	―	―

Venture Life Corporate Events

Venture Life Buys Back 200,000 Shares, Updates Voting Rights

Venture Life Group has repurchased 200,000 of its own ordinary shares at a volume-weighted average price of 66.96p under its ongoing share buyback programme, with the shares to be held in treasury. Following this transaction and the recent admission of new shares from option exercises, the company now has 128,737,145 ordinary shares in issue, of which 1,939,981 are held in treasury, leaving 126,797,164 voting rights outstanding, a figure that will guide shareholders in monitoring and disclosing changes to their holdings under UK regulatory rules.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £66.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Venture Life Confirms Total Voting Rights Following Year-End Share Capital Update

Venture Life Group has confirmed that, as of 31 December 2025, it has 128,253,812 ordinary shares of 0.3 pence in issue, of which 1,739,981 are held in treasury, leaving 126,513,831 shares carrying voting rights. The company noted that this total voting rights figure will serve as the reference point for shareholders in determining whether they must disclose holdings or changes in their interests under the FCA’s Disclosure Guidance and Transparency Rules, providing clarity and transparency over the group’s current capital and governance structure.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £66.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Venture Life CEO Exercises Options as Group Updates Total Voting Rights

Venture Life Group has issued 483,333 new ordinary shares following the exercise of share options by chief executive Jerry Randall under the company’s Long-Term Incentive Plan, at an exercise price of 41 pence per share, increasing his beneficial holding to 2,736,533 shares, or about 2.13% of the company’s issued share capital. The new shares are expected to be admitted to trading on AIM on 7 January 2025, taking the total shares in issue to 128,737,145, of which 1,739,981 are held in treasury, and setting the company’s voting rights at 126,997,164, a reference figure for investors monitoring disclosure thresholds under UK market transparency rules.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £66.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Venture Life Buys Back 145,780 Shares for Treasury Under Ongoing Programme

Venture Life Group has repurchased 145,780 ordinary shares at a volume-weighted average price of 65.75 pence per share under its ongoing share buyback programme, with the shares to be held in treasury. Following this transaction, the company has 128,253,812 ordinary shares in issue, of which 1,739,981 are held in treasury, resulting in 126,513,831 voting rights, a change that may affect shareholders’ disclosure thresholds under UK transparency rules and underscores the group’s continued capital management initiatives.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £66.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Venture Life Buys Back 30,212 Shares Under Ongoing Repurchase Programme

Venture Life Group has repurchased 30,212 ordinary shares at a volume-weighted average price of 65.44 pence per share under its ongoing share buyback programme, with the shares to be held in treasury. Following this transaction, the company has 128,253,812 ordinary shares in issue, of which 1,594,201 are held in treasury, leaving 126,659,611 voting rights in circulation, a figure relevant for investors monitoring their disclosure obligations under UK transparency rules and signalling continued capital management activity by the group.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £66.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Venture Life Buys Back 200,000 Shares for Treasury Under Ongoing Programme

Venture Life Group has continued to execute its previously announced share buyback programme with the market repurchase of 200,000 ordinary shares at a volume-weighted average price of 65.64p, with the shares to be held in treasury. Following this latest transaction, the company’s total shares in issue stand at 128,253,812, of which 1,563,989 are held in treasury, leaving 126,689,823 voting shares outstanding, a figure that will guide investors’ disclosure calculations and marginally enhance earnings per share and capital management flexibility.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £66.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Venture Life Buys Back 200,000 Shares, Updates Voting Rights Total

Venture Life Group has repurchased 200,000 of its ordinary shares at a volume-weighted average price of 65.90 pence as part of its ongoing share buyback programme, with the shares to be held in treasury. Following this transaction and the recent admission of 201,500 new shares from option exercises, the company will have 128,253,812 ordinary shares in issue, of which 1,363,989 are held in treasury, leaving 126,889,823 voting shares outstanding, a figure shareholders can use to assess disclosure thresholds under FCA transparency rules.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £66.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Venture Life Buys Back 300,000 Shares, Updates Voting Rights Total

Venture Life Group has repurchased 300,000 of its own ordinary shares at a volume-weighted average price of 65.97 pence per share under its ongoing share buyback programme, with the shares to be held in treasury. Following this transaction and the recent issuance of 201,500 new shares from option exercises, the company now has 128,253,812 ordinary shares in issue, of which 1,163,989 are held in treasury, leaving 127,089,823 voting rights in circulation, a figure investors can use to assess and report changes in their holdings under regulatory disclosure rules.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £66.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Venture Life Increases Share Capital After Employee Option Exercise

Venture Life Group has issued 201,500 new ordinary shares following the exercise of share options by employees, with the shares expected to be admitted to trading on AIM on 24 December 2025. Following this admission, the company will have 128,253,812 ordinary shares in issue, of which 863,989 are held in treasury, resulting in 127,389,823 voting rights, a figure that shareholders can use to assess whether they must disclose changes in their holdings under UK transparency rules.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £66.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Venture Life Executes Share Buyback Program

Venture Life Group PLC has executed a share buyback program, purchasing 35,279 ordinary shares at a volume-weighted average price of 61.92 pence per share. These shares will be held as treasury shares, impacting the company’s total voting rights, which now stand at 127,268,304. This move is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £66.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Venture Life Executes Share Buyback Programme

Venture Life Group PLC has executed a share buyback, purchasing 144,721 ordinary shares at a volume-weighted average price of 61.76 pence per share. This transaction is part of their share buyback programme announced earlier, and the acquired shares will be held as treasury shares. Following this repurchase, the total number of voting rights in the company stands at 127,303,583. This move is likely to impact the company’s stock liquidity and may influence shareholder value, reflecting a strategic decision to manage capital and shareholder interests.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £66.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Venture Life Group Executes Share Buyback Program

Venture Life Group PLC has executed a share buyback program, acquiring 52,690 ordinary shares at a volume-weighted average price of 61.82 pence per share. These shares will be held as treasury shares, impacting the total number of voting rights in the company, which now stands at 127,448,304. This move is part of the company’s ongoing efforts to manage its capital structure and may influence shareholder calculations under the FCA’s Disclosure Guidance and Transparency Rules.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £66.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Venture Life Executes Share Buyback Program

Venture Life Group PLC has executed a share buyback, purchasing 10,000 ordinary shares at a volume-weighted average price of 61.51 pence per share. This move, part of a previously announced buyback program, results in the company holding 551,318 shares in treasury, with a total of 128,052,312 ordinary shares in issue. The buyback could potentially impact shareholder voting rights and reflects the company’s strategic financial management.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £66.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Venture Life Executes Share Buyback Program

Venture Life Group PLC, a leader in the global consumer healthcare sector, has executed a share buyback program, purchasing 65,000 ordinary shares at a volume-weighted average price of 61.59 pence per share. These shares will be held as treasury shares, and the total number of voting rights in the company will be adjusted accordingly. This move is part of the company’s strategic financial management to optimize shareholder value and may influence stakeholders’ interest calculations under regulatory guidelines.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £66.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Venture Life Sells Non-Core Oral Care Assets to Focus on Core Brands

Venture Life Group PLC has completed the sale of its non-core Oral Care Assets, including Ultradex and Dentyl brands, to Covestus Holdings Ltd for up to £4.5 million. This divestment aligns with Venture Life’s strategic focus on its higher margin, higher growth core brands, and the proceeds will be used to bolster its acquisition strategy and drive innovation in its core product categories. The sale also allows the company to streamline operations and focus on its Power Brands, promoting proactive healthy longevity for consumers.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £66.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Venture Life Group Executes Share Buyback Program

Venture Life Group PLC has executed a share buyback, purchasing 25,000 ordinary shares at a volume-weighted average price of 61.15 pence per share, as part of its previously announced buyback program. The repurchased shares will be held as treasury shares, affecting the total number of voting rights, which now stands at 127,575,994. This move is part of the company’s strategy to manage its capital structure and may impact shareholder calculations under the FCA’s rules.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £66.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Venture Life Executes Share Buyback Program

Venture Life Group PLC has executed a share buyback program, purchasing 75,000 ordinary shares at a volume-weighted average price of 60.50 pence per share. The acquired shares will be held as treasury shares, adjusting the total number of voting rights in the company to 127,600,994. This move is part of the company’s strategy to manage its capital structure and could potentially impact shareholder value and market perception.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £57.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Venture Life Announces Total Voting Rights Update

Venture Life Group PLC announced its total voting rights as of 30 November 2025, with 127,675,994 ordinary shares carrying voting rights out of a total issued share capital of 128,052,312 shares. This information is crucial for shareholders to determine their interest in the company’s share capital under the FCA’s Disclosure and Transparency Rules.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £57.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Venture Life Executes Share Buyback Program

Venture Life Group PLC, a leader in proactive healthy longevity within the global consumer healthcare sector, has executed a share buyback program, purchasing 75,000 ordinary shares at a volume-weighted average price of 60.57 pence per share. This move, facilitated by Cavendish Capital Markets Limited, results in a total of 128,052,312 ordinary shares in issue, with 376,318 held in treasury, impacting the total number of voting rights and potentially influencing shareholder interest notifications under FCA’s rules.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £57.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Venture Life Executes Share Buyback Program

Venture Life Group PLC has executed a share buyback, purchasing 10,000 ordinary shares at a volume-weighted average price of 60.56 pence per share. This action is part of their ongoing share buyback program, and the acquired shares will be held as treasury shares. Following this transaction, the company has 128,052,312 ordinary shares in issue, with 301,318 held in treasury, impacting the total voting rights available to shareholders. This move reflects the company’s strategic financial management and may influence shareholder calculations under the FCA’s Disclosure Guidance and Transparency Rules.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £57.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Venture Life Executes Share Buyback Program

Venture Life Group PLC has executed a share buyback program, purchasing 65,479 ordinary shares at a volume-weighted average price of 58.21 pence per share. These shares will be held as treasury shares, impacting the company’s total voting rights, which now stand at 127,760,994. This strategic move is part of the company’s ongoing efforts to manage its capital structure and may influence shareholder calculations under the FCA’s Disclosure Guidance and Transparency Rules.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £57.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Venture Life Group Executes Share Buyback to Optimize Capital Structure

Venture Life Group PLC has executed a share buyback, purchasing 20,000 ordinary shares at a price of 59.21 pence each, as part of its ongoing share buyback programme. The acquired shares will be held as treasury shares, adjusting the total number of voting rights in the company to 127,826,473. This move is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £57.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Venture Life Group Executes Share Buyback Program

Venture Life Group PLC has executed a share buyback, purchasing 120,000 ordinary shares at a volume-weighted average price of 57.81 pence per share, as part of its share buyback program. This transaction, conducted through Cavendish Capital Markets Limited, results in the company holding these shares as treasury shares, impacting the total number of voting rights available. The move is likely aimed at optimizing the company’s capital structure and potentially increasing shareholder value.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £57.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Venture Life Executes Share Buyback Program

Venture Life Group PLC has executed a share buyback program, purchasing 61,599 ordinary shares at an average price of 58.9025 pence per share. These shares will be held as treasury shares, affecting the total number of voting rights in the company, which now stands at 127,966,473. This move is part of the company’s strategic financial management, potentially impacting shareholder value and market perception.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £57.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Venture Life Executes Share Buyback to Strengthen Capital Structure

Venture Life Group PLC, a leader in the global consumer healthcare sector, has executed a share buyback program, acquiring 24,240 ordinary shares at an average price of 59.65 pence each. These shares will be held as treasury shares, affecting the total voting rights in the company, which now stands at 128,028,072. This move is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £57.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.